9 November 2017  
EMA/CHMP/452568/2017  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Genvoya 
elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide 
On 9 November 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Genvoya. The marketing authorisation holder for this medicinal product is Gilead Sciences International 
Ltd. 
The CHMP adopted an extension to the existing indication as follows2: 
"Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body 
weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) infection without any 
known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir, as 
follows: (see sections 4.2 and 5.1). 
• 
• 
In adults and adolescents aged from 12 years and with body weight at least 35 kg 
In children aged from 6 years and with body weight at least 25 kg for whom alternative 
regimens are unsuitable due to resistance or toxicities. 
See sections 4.2, 4.4 and 5.1.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
